Open label study of the effect of amantadine on weight gain induced by olanzapine

Psychiatry and Clinical Neurosciences

Volumn 58, Issue 2, 2004, Pages 163-167

  Bahk, Won Myong ^a   Lee, Kyoung Uk ^a   Chae, Jeong Ho ^a   Pae, Chi Un ^a   Jun, Taeyoun ^a   Kim, Kwang Soo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Amantadine; Olanzapine; Weight gain

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; OLANZAPINE; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; OPEN STUDY; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ADULT; AMANTADINE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BODY MASS INDEX; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 1842635040     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2003.01211.x     Document Type: Article

References (33)

1. Kaplan HI, Sadock BJ. Synopsis of Psychiatry, 8th edn. Wiliams & Wilkins, Baltimore, 1998; 1069-1081.
2. Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 1999; 156: 702-709.
3. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2000; 2 (3 Part 1): 196-199.
4. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-167.
5. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-123.
6. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997; 154: 457-465.
7. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry 1997; 58: 45-49.
8. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999; 156: 1686-1696.
9. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes. Res. 1998; 6: 97-106.
10. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208: 1168-1170.
11. Sadock BJ, Sadock VA. Comprehensive Textbook of Psychiatry, 7th edn. Wiliams & Wilkins, Philadelphia, 2000.
12. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J. Clin. Psychopharmacol. 1987; 7: 91-95.
13. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur. Neuropsychopharmacol. 2001; 11: 181-182.
14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Press, New York, NY, 1995.
15. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962; 10: 799-812.
16. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J. Clin. Psychiatry 1979; 40: 147-152.
17. Planansky K. Changes in weight in patients receiving a tranquilizing drug. Psychiatr. Q. 1958; 32: 289-303.
18. Amdisen A. Drug produced obesity. Experiences with chlorpromazine, perphenazine, and clopenthixol. Dan. Med. Bull. 1964; 11: 182-189.
19. Harris E, Eth S. Weight gain during neuroleptic treatment. Int. J. Nurs. Stud. 1981; 18: 171-175.
20. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 2002; 14: 123-129.
21. Beasley CM Jr, Hamilton SH, Crawford AM et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 1997; 7: 125-137.
22. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2001; 158: 765-774.
23. Ganguli R. Weight gain associated with antipsychotic drugs. J. Clin. Psychiatry 1999; 60 (Suppl. 21): 20-24.
24. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J. Clin. Psychiatry 2001; 62 (Suppl. 2): 41-44.
25. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 2001; 62: 92-100.
26. Baptista T, Lopez ME, Teneud L et al. Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 1997; 30: 43-54.
27. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr. Bull. 1995; 21: 463-472.
28. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 2003; 37: 193-220.
29. Hausner RS. Amantadine-associated recurrence of psychosis. Am. J. Psychiatry 1980; 137: 240-242.
30. Doraiswamy M, Martin W, Metz A, Deveaugh-Geiss J. Psychosis in Parkinson's disease: diagnosis and treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995; 19: 835-846.
31. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J. Neurol. 2001; 248 (Suppl. 3): III28-III31.
32. Yamada K, Kanba S, Ohnishi K, Ashikari I, Yagi G, Asai M. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia. Biol. Psychiatry 1997; 41: 1062-1064.
33. Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. 1992; 213: 439-443.